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Abstract  Gastric  antral  vascular  ectasia  (GAVE)  is  a  capillary-type  vascular  malformation  of  the
gastric antrum  and  an  infrequent  cause  of  chronic  gastrointestinal  blood  loss  and  iron  deﬁciency
anemia.
The authors  describe  a  case  report  of  GAVE  in  a  female  cirrhotic  patient  presenting  with
severe symptomatic  iron  deﬁciency  anemia.  After  failure  of  argon  plasma  coagulation  (APC),
the patient  was  treated  with  endoscopic  band  ligation  (EBL)  with  resolution  of  anemia,  without
new episodes  of  rebleeding  and  no  need  for  further  hospitalizations  or  transfusion  requirements.
Even though  APC  is  the  current  treatment  of  choice  for  GAVE  recurrence-free  survival  at  one
year is  achieved  in  less  than  50%  of  the  patients  and  failed  therapy  has  been  described  in  up  to
14% of  the  patients.  EBL  has  been  reported  to  be  a  relatively  easy  technique  for  GAVE  therapy
and has  been  shown  to  be  safe  and  effective  with  lower  complication  rates  in  comparison  with
APC. This  technique  may  in  the  future  be  used  as  the  initial  endoscopic  treatment  to  eradicate
GAVE.
© 2016  Sociedade  Portuguesa  de  Gastrenterologia.  Published  by  Elsevier  Espan˜a,  S.L.U.  This  is
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etiológico  de  anemia  ferropénica  sintomática.  Após  falência  do  tratamento  endoscópico  com
árgon plasma  (APC),  a  doente  foi  submetida  a  laqueac¸ão  elástica  da  GAVE  com  resoluc¸ão  da
anemia, sem  novos  episódios  de  hemorragia  e  sem  necessidade  de  re-internamentos  ou  suporte
transfusional.
Apesar do  APC  ser  o  tratamento  de  primeira  linha  para  a  GAVE  a  taxa  de  doentes  sem  recor-
rência em  um  ano  é  alcanc¸ada  em  menos  de  50%  dos  doentes,  para  além  de  falências  primárias
ao tratamento  rondarem  os  14%.  A  laqueac¸ão  elástica  tem  sido  descrita  como  uma  técnica  de
fácil aplicac¸ão  no  tratamento  da  GAVE  e  tem-se  revelado  segura,  eﬁcaz  e  com  baixa  taxa  de
complicac¸ões em  comparac¸ão  com  o  APC.  Esta  técnica  pode,  no  futuro,  ser  utilizada  como
tratamento  endoscópico  inicial  para  a  erradicac¸ão  da  GAVE.
© 2016  Sociedade  Portuguesa  de  Gastrenterologia.  Publicado  por  Elsevier  Espan˜a,  S.L.U.  Este




















































astric  antral  vascular  ectasia  (GAVE)  is  a  capillary-type
ascular  malformation  of  the  gastric  antrum1 and  an  infre-
uent  cause  of  chronic  gastrointestinal  blood  loss  and  iron
eﬁciency  anemia.  GAVE  is  responsible  for  up  to  4%  of  non-
ariceal  upper  gastrointestinal  (GI)  bleeding  and  6%  of  upper
I  bleeding  in  cirrhotic  patients.2,3
Most  cases  are  idiopathic,  but  it  is  frequently  associ-
ted  with  other  clinical  conditions,  such  as  cirrhosis  and
utoimmune  diseases,4 with  a  prevalence  reported  in  cir-
hotic  patients  of  12%3 and  reaching  30%  in  patients  with
iver  failure.5
At  oesophagogastroduodenoscopy  (OGD),  GAVE  may
ppear  as  multiple  longitudinal  streaks  that  converge  at
he  pyloric  oriﬁce,  with  a  ‘‘watermelon’’  pattern  (stripe
ype),  or  as  multiple  erythematous  spots  (diffuse  or  granular
ype).6 This  last  form  occurring  more  frequently  in  patients
ith  cirrhosis.6
The  current  treatment  of  choice  for  GAVE  is  endoscopic
ntervention  with  argon  plasma  coagulation  (APC).7 However
ecurrence-free  survival  at  one  year  is  achieved  in  less  than
0%  of  the  patients8 and  in  addition  rates  of  failed  therapy
f  up  to  14%  have  been  reported.3 Equally  important  to  refer
s  the  complication  rate  which  is  high  (20--30%).3
The  authors  describe  a  case  report  of  GAVE  in  a  female
irrhotic  patient  presenting  with  severe  symptomatic  iron
eﬁciency  anemia.  After  failure  of  APC,  the  patient  was
reated  with  endoscopic  band  ligation  (EBL)  with  resolution
f  anemia,  without  new  episodes  of  rebleeding  and  no  need
or  further  hospitalizations  or  transfusion  requirements.
. Case presentation
 69-years-old  female  presented  with  a  three-week  history
f  fatigue.  She  denied  hematemesis  and  abdominal  pain,  and
here  was  no  change  in  appetite,  weight,  bowel  pattern,  or
tool  color.  She  had  a  medical  history  of  alcoholic  cirrho-
is  (Child  Pugh  A,  MELD  7  points)  and  was  on  furosemide,
ad  no  known  allergies  and  no  family  history  of  gastroin-
estinal  pathology.  She  denied  consumption  of  nonsteroidal




pFigure  1  Gastric  antral  vascular  ectasia.
Physical  examination  revealed  paleness  of  the  skin  and
ucosae  and  sinus  tachycardia  with  normal  blood  pressure.
ectal  examination  did  not  reveal  blood  in  stools.
Laboratory  data  evidenced  severe  anemia  with
emoglobin  level  of  4.0  g/dL,  low  platelet  count,  nor-
al  coagulation  parameters  and  inﬂammatory  markers
ere  normal.  Iron  study  revealed  a serum  iron  level  of
4  g/dL  (reference  range  50--170  g/dL)  with  a  total
ron  binding  capacity  of  398  g/dL  (reference  range
50--450  g/dL)  and  ferritin  of  2.8  ng/mL  (reference  range
--252  ng/mL).  Transfusion  of  red  blood  cells  was  initiated
ith  hemoglobin  level  increasing  to  7.7  g/dL.
An  OGD  was  performed  and  revealed  multiple  erythema-
ous  spots  in  the  antrum  compatible  with  GAVE,  diffuse  type
Fig.  1),  and  mild  portal  hypertensive  gastropathy,  with-
ut  active  bleeding.  There  was  no  evidence  of  esophageal
r  gastric  varices.  GAVE  was  treated  with  APC  without
omplications  (Fig.  2).  A  colonoscopy  with  ileoscopy  was
lso  performed,  but  it  was  negative  for  blood  or  hemor-
hagic  lesions.  Her  hemoglobin  levels  remained  stable  and
he  patient  was  discharged  and  started  on  propranolol  (for
ortal  hypertensive  gastropathy),  with  a  target  of  55  beats


















aFigure  2  Gastric  antral  vascular  ectasia  --  after  APC  treat-
ment.
per  minute,  40  mg  of  pantoprazole  every  24  h  and  performed
iron  intravenous  supplementation  in  ambulatory.
During  the  following  4  months,  the  patient  had  3  new
episodes  of  severe  symptomatic  anemia  requiring  trans-
fusion.  During  these  episodes  she  underwent  OGD  that
revealed  persistence  of  GAVE  and  APC  treatments  were  per-
formed.
Nevertheless  the  patient  presented  with  a  new  episode
of  symptomatic  anemia,  and  an  hemoglobin  level  of  3.7  g/dL
was  observed.  After  transfusion  of  red  blood  cells  an  OGD
was  performed.  At  that  time,  since  GAVE  persisted  despite
treatment  sessions  using  APC,  and  taking  into  consideration
the  severity  and  short  recurrence  intervals  of  symptomatic
anemia,  a  decision  was  made  to  perform  EBL  (multi-band  lig-
ator,  Ezy  Shoot,  G-Flex®).  Six  bands  were  applied,  starting
from  lesions  adjacent  to  the  pylorus,  then  continued  proxi-
mally  in  the  antrum  until  most  of  the  GAVE  affected  areas
were  treated  (Fig.  3).  No  complications  of  the  procedure
were  reported,  and  the  patient  was  discharged  after  24  h,
maintaining  propranolol  and  pantoprazole.  Endoscopic  eval-
uation  was  performed  every  4  weeks  and  another  3  sessions
of  EBL  were  performed  with  almost  complete  eradication  of
GAVE  (Fig.  4).  Following  the  ﬁrst  EBL  treatment  the  patient





Figure  3  EBL  treatment.igure  4  Gastric  antral  vascular  ectasia  --  after  EBL  treatment
4 sessions).
2  g/dL  and  no  need  of  red  cells  blood  transfusion  or  iron
upplementation.
.  Discussion
AVE  is  a  poorly  understood  entity,  of  unknown  etiology,
nd  an  increasingly  identiﬁable  cause  of  chronic  iron  deﬁ-
iency  anemia.  The  pharmacological  management  of  GAVE
as  been  met  with  disappoint  results,  and  the  mainstay  of
AVE  management  remains  endoscopic  therapy.3,9
APC  is  a  modality  of  non-contact  electrocoagulation  that
pplies  high-frequency  energy  into  tissue  to  cause  ther-
al  effects,  which  can  be  used  for  hemostasis.10 APC  has
een  used  successfully  to  treat  GAVE  with  an  effective  tran-
ient  response,  but  primary  failure  rates  of  therapy  of  up
o  14%  have  been  reported.3 Some  authors11--13 suggest  that
his  endoscopic  modality  is  insufﬁcient  in  order  to  achieve
edium  and  long-term  treatment  success,  as  it  has  been
ssociated  with  a  high  recurrence  rate  (40--100%),  with  less
han  50%  of  the  patients  achieving  a recurrence-free  sur-
ival  at  one  year.8 In  addition  to  this  limitation,  APC  results
n  complications,  such  as  sepsis,  pyloric  stenosis  and  gastric









































































festations of watermelon stomach. Endoscopy. 2003;35:1024--8.52  
EBL  has  been  reported  to  be  a  relatively  easy  technique
or  GAVE  therapy,  has  been  shown  to  be  safe  and  effective
ith  lower  complication  rates  in  comparison  with  APC.14,15
 recent  prospective  study  showed  endoscopic  improve-
ent  with  the  use  of  EBL  in  91%  of  the  patients,  associated
ith  a  signiﬁcant  improvement  in  the  hemoglobin  and  fer-
itin  levels.  EBL  in  GAVE  has  been  associated  with  transient
bdominal  pain  in  a  minority  of  the  patients  but  no  major
omplications  have  been  reported  in  the  literature.14
Another  new  option  therapy  for  GAVE  is  radiofrequency
blation,  which  allows  larger  mucosal  surfaces  to  be
reated.  A  recent  study16 suggests  that  radiofrequency  abla-
ion  is  a  safe  and  effective  treatment  for  recurrent  bleeding
rom  GAVE.  However  this  technique  requires  additional
raining,  is  more  expensive  than  other  options  and  is  not
idely  available.16 Potential  complications  are  the  same  as
or  APC  and  includes  perforation  and  bleeding.16
In  this  case,  the  patient  was  initially  treated  with  APC
fter  being  diagnosed  with  GAVE  as  the  cause  of  severe  iron
eﬁciency  anemia,  however  this  strategy  was  not  successful.
PC  treatment  might  not  be  effective  in  some  cases  and  this
ould  be  explained  by  the  limited  depth  of  thermal  injury.10
Even  tough  portal  hypertensive  gastropathy  was  mild  and
robably  not  the  cause  of  anemia,  because  of  the  severe
resentation  without  active  bleeding,  the  patient  started
n  propranolol  which  is  the  ﬁrst  line  treatment  to  reduce
ortal  pressure.9
EBL  is  widely  employed  as  an  effective  treatment  for
sophageal  varices  because  of  its  capacity  to  obliterate  sub-
ucosal  varices.  With  respect  to  GAVE,  since  the  histological
hanges  are  present  in  the  mucosa  and  submucosal  layer,
BL  may  be  more  effective  because  of  its  ability  to  oblit-
rate  the  submucosal  vascular  plexus.10 In  this  patient,  the
resence  of  extensive  areas  of  the  antrum  affected  with  a
igh-density  of  both  mucosal  and  submucosal  vascular  mal-
ormations  is  a  likely  explanation  for  the  primary  failure
f  the  APC  treatment.  Given  the  fast  recurrence  of  severe
nemia,  often  within  4  weeks,  the  decision  to  perform  EBL
ielded  positive  results,  with  eradication  of  GAVE  with  4
essions  of  EBL  with  no  complications,  namely  abdominal
ain.
Even  though  our  case  report  is  in  accordance  with  recent
iterature  some  issues  still  need  to  be  elucidated  in  order
o  improve  the  treatment  of  GAVE  with  EBL.  The  optimal
nterval  between  treatment  sessions,  the  potential  role  of
ombined  therapy  with  APC  in  patients  with  poor  response
nd  the  need  of  endoscopic  surveillance  for  recurrence  after
radication  since  the  etiology  of  GAVE  are  still  unknown.
Some  studies14,15 suggest  that  the  number  of  sessions
equired  for  GAVE  eradication  is  inferior  when  using  EBL
ompared  to  APC,  resulting  in  inferior  health  care  costs
or  that  group  of  patients.  However,  randomized  controlled
rials  are  lacking  to  determine  whether  EBL  is  more  cost
ffective  than  APC  as  the  primary  endoscopic  therapy  for
AVE.
In  summary,  GAVE  is  a  rare  cause  of  chronic  gastrointesti-
al  blood  loss  and  iron  deﬁciency  anemia,  often  associated
ith  chronic  diseases  such  as  cirrhosis.  We  report  an
nusual  case  of  GAVE  with  severe  symptomatic  anemia,
ith  no  response  to  primary  endoscopic  therapy  with  APC
espite  correct  intravenous  iron  supplementation  between
ndoscopic  treatments.  After  initiating  GAVE  eradication
1Dias  de  Castro  F  et  al.
ith  EBL  the  patient  became  asymptomatic.  EBL  may  in
he  future  be  used  as  the  initial  endoscopic  treatment  to
radicate  GAVE,  but  larger  studies  are  needed  to  clarify  this
ssue.
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